Militia Capital Management LLC Buys Shares of 22,800 Icon Plc $ICLR

Militia Capital Management LLC purchased a new position in shares of Icon Plc (NASDAQ:ICLR) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 22,800 shares of the medical research company’s stock, valued at approximately $2,523,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. NewEdge Advisors LLC raised its stake in shares of Icon by 109.2% during the first quarter. NewEdge Advisors LLC now owns 2,738 shares of the medical research company’s stock valued at $303,000 after purchasing an additional 1,429 shares in the last quarter. Arkadios Wealth Advisors lifted its holdings in Icon by 87.6% in the first quarter. Arkadios Wealth Advisors now owns 29,843 shares of the medical research company’s stock worth $3,302,000 after purchasing an additional 13,939 shares during the period. Amundi grew its position in Icon by 88.6% in the 1st quarter. Amundi now owns 33,583 shares of the medical research company’s stock valued at $3,716,000 after buying an additional 15,773 shares in the last quarter. Royal Bank of Canada grew its position in Icon by 68.0% in the 1st quarter. Royal Bank of Canada now owns 153,728 shares of the medical research company’s stock valued at $17,011,000 after buying an additional 62,225 shares in the last quarter. Finally, Eagle Health Investments LP increased its stake in Icon by 45.1% during the 1st quarter. Eagle Health Investments LP now owns 358,500 shares of the medical research company’s stock valued at $39,672,000 after buying an additional 111,410 shares during the period. Institutional investors own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on ICLR. Piper Sandler downgraded shares of Icon to a “neutral” rating in a research report on Thursday, May 28th. Royal Bank Of Canada upgraded shares of Icon from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $126.00 to $185.00 in a research note on Thursday, June 25th. Jefferies Financial Group reissued a “buy” rating and set a $165.00 target price on shares of Icon in a report on Friday, May 29th. Barclays upped their target price on Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 25th. Finally, Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $170.40.

Icon News Summary

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Truist reaffirmed its “Buy” rating and raised its price target to $209 from $207, implying substantial upside based on the referenced share price. The target increase signals continued confidence in Icon’s long-term growth prospects. Benzinga analyst rating report
• Positive Sentiment: Icon reported second-quarter revenue of approximately $2.06 billion, above the roughly $2.00 billion consensus estimate, with revenue growing 2.3% from the prior-year period. The earnings call also emphasized a strong surge in bookings, supporting future revenue visibility. Q2 2026 earnings call highlights
• Positive Sentiment: Zacks upgraded ICLR from “Strong Sell” to “Hold,” suggesting its view has improved even though the firm remains cautious. Zacks rating update
• Neutral Sentiment: Quarterly adjusted EPS was $2.56, narrowly above some consensus estimates of $2.55, although another Zacks estimate was $2.57. The mixed comparison makes the earnings beat less decisive for investors. Icon Q2 earnings snapshot
• Negative Sentiment: EPS fell sharply from $3.26 a year earlier, while the earnings call highlighted margin pressures. The weaker profitability, despite higher revenue and bookings, is likely the main factor tempering the bullish analyst commentary. ICON Q2 2026 earnings call transcript

Icon Price Performance

Shares of Icon stock opened at $163.57 on Monday. Icon Plc has a 52 week low of $66.57 and a 52 week high of $203.91. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.23. The stock has a market cap of $12.52 billion, a PE ratio of 38.40, a price-to-earnings-growth ratio of 8.03 and a beta of 1.22. The company’s 50-day moving average price is $156.70 and its two-hundred day moving average price is $135.31.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, July 29th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The company had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2 billion. During the same quarter in the previous year, the company posted $3.26 EPS. The business’s revenue was up 2.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Icon Plc will post 9.43 EPS for the current fiscal year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.